Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis

Shadi Baniasadi, Fanak Fahimi, Payam Tabarsi, Seyed Alireza Nadji, Shadi Khabiri, Nahid Shahsavari, Farzad Kobarfard
European Respiratory Journal 2012 40: P2630; DOI:
Shadi Baniasadi
1Virology Research Center, Natonal Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanak Fahimi
2Chronic Respiratory Disease Research Center, Natonal Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Payam Tabarsi
2Chronic Respiratory Disease Research Center, Natonal Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seyed Alireza Nadji
1Virology Research Center, Natonal Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shadi Khabiri
2Chronic Respiratory Disease Research Center, Natonal Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nahid Shahsavari
3Medicinal Chemistry Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farzad Kobarfard
3Medicinal Chemistry Department, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction: Therapeutic drug monitoring (TDM) is the process of adjusting drug dosages based on serum concentration data. Several reports have shown altered pharmacokinetic profiles for the anti-tuberculosis (TB) drugs in HIV patients. Such patients may benefit from TDM and early interventions may prevent the development of further drug resistance.

Aims: This study aimed to determine serum isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) concentrations in a cohort of patients with HIV-related TB who were treated in a referral TB center.

Methods: Twenty HIV-infected patients who received 4 first-line anti-TB drugs for active TB were eligible for the study. Venous blood was obtained 2 h after daily dose of INH (5mg/kg), RIF (10 mg/kg), and PZA (25 mg/kg). Serum levels of anti-TB drugs were analyzed using high –pressure liquid chromatography (HPLC) and compared with published normal ranges.

Results: Of the 20 patients (mean age 36.25 years, range 30-57 years), 18 (90%) had a very low maximum concentration of INH (<1 µg/mL), and 2 (10%) had a low maximum concentration of INH (<2 µg /mL). All patients had a very low maximum concentration of RIF (<7 µg /mL) and 7 (35%) had a low maximum concentration of PZA (<20 µg /mL).

Conclusions: Low serum concentrations of INH, RIF, and PZA, which may be related to malabsorption, are common in HIV-infected TB patients. TDM of anti-TB drugs may helps clinicians to optimize drug therapy and improve TB cure rates.

  • Pharmacology
  • Infections
  • Treatments
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis
Shadi Baniasadi, Fanak Fahimi, Payam Tabarsi, Seyed Alireza Nadji, Shadi Khabiri, Nahid Shahsavari, Farzad Kobarfard
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2630;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis
Shadi Baniasadi, Fanak Fahimi, Payam Tabarsi, Seyed Alireza Nadji, Shadi Khabiri, Nahid Shahsavari, Farzad Kobarfard
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2630;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia)
  • Digital health technology for the end TB strategy: Developing priority products and making them work
  • Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT)
Show more 10.2 Tuberculosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society